Oncology

A combination of vemurafenib (Zelboraf) and experimental drug cobimetinib significantly reduces the development of secondary skin cancer.

The results of an FDA safety review of omalizumab (Xolair) suggest the asthma drug slightly elevates the risk of serious cardiovascular and cerebrovascular adverse events.

A combination of Lactobacillus plantarum and a modified inulin derivative reduced expression of T-cells in mammary cancers induced in rats.

RX-3117 maintains anti-tumor activity in cancer cell lines that are resistant to gemcitabine.

A recent metaanalysis suggests that prediabetes increases the risk of developing certain cancers, particularly in tissues located near the gastrointestinal tract.

RX-3117 maintains anti-tumor activity in cancer cell lines that are resistant to gemcitabine.

Researchers in Japan are beginning to construct patient-centered counseling techniques for breast cancer by evaluating patient preference.

Amgen has submitted a new drug application to the FDA for its novel leukemia candidate, blinatumomab.

One major challenge in breast cancer is determining which treatment will be most effective for an individual patient's tumor. With a genetic panel, the TAXSig system may help change that.

Protein found to play vital role in development of disease.

Researchers find 23 new prostate cancer risk sites on the genome.

Baldness on front and crown of head linked to increased chance of developing aggressive prostate cancer.

A prognostic disease marker that often occurs in patients with triple-negative breast cancer may lead to development of a medication to close a therapeutic gap in targeted cancer treatment.

The FDA has expanded the approval for enzalutamide (Xtandi) to include the treatment of men with chemotherapy-naive metastatic castration-resistant prostate cancer.

For patients, having many treatment options can add to the stress of a cancer diagnosis.

Regina, a licensed pharmacist for more than 20 years, developed breast cancer at 48 years of age.

A recent meta-analysis published in the journal Plos One indicates a potential link between breast cancer and use of a common blood pressure medication, but a closer look tells a different story.

Pembrolizumab is the first drug approved that blocks the PD-1 cellular pathway.

Medicaid beneficiaries are more likely to be screened for 3 types of cancer in states where physicians receive higher payments for office visits, a study suggests.

Specialty therapies for rheumatoid arthritis, multiple sclerosis, and breast cancer tended to have positive functional and clinical outcomes for patients.

Investigators in Europe have confirmed the effectiveness of prostate-specific antigen screening in reducing the risk of cancer-related mortality and in detecting a larger share of prostate cancer cases.